chapter 33 anti diabetic drugs - week 3 Flashcards
diabetes
Often regarded as a syndrome rather than a disease
Two types
Type 1
Type 2
diabetes signs and symptoms
Signs and symptoms
Elevated fasting blood glucose (higher than 7 mmol/L) or a hemoglobin A1c (HbA1c) level greater than or equal to 6.5%
Polyuria
Polydipsia
Polyphagia
Glycosuria
Weight loss
Fatigue
Blurred vision
diabetes signs and symptoms
Signs and symptoms
* Elevated fasting blood glucose (higher than 7 mmol/L) or a hemoglobin A1c (HbA1c) level greater than or equal to 6.5%
* Polyuria
* Polydipsia
* Polyphagia
* Glycosuria
* Weight loss
* Fatigue
* Blurred vision
type 1 diabetes
- Lack of insulin production, or production of defective insulin
- Affected patients need exogenous insulin.
- Fewer than 10% of all cases are type 1.
Complications
* Diabetic ketoacidosis
* Hyperosmolar hyperglycemic state
type 2
- Most common type (90% of all cases)
- Caused by insulin deficiency and insulin resistance
Many tissues are resistant to insulin.
* Reduced number of insulin receptors
* Insulin receptors less responsive
Several comorbid conditions
* Obesity
* Coronary heart disease
* Dyslipidemia
* Hypertension
* Microalbuminemia (protein in the urine)
* Increased risk for thrombotic (blood clotting) events
* These comorbidities are collectively referred to as metabolic syndrome or cardiometabolic syndrome.
gestational diabetes
- Hyperglycemia that develops during pregnancy
- Insulin must be given to prevent birth defects.
- Usually subsides after delivery
- 30% of patients may develop type 2 diabetes within 10 to 15 years.
major long term complications of both types of diabetes
Macrovascular (atherosclerotic plaque)
Coronary arteries
Cerebral arteries
Peripheral vessels
Microvascular (capillary damage)
Retinopathy
Neuropathy
Nephropathy
screening for diabetes
Prediabetes
Categories of increased risk
* HbA1c of 6.0 to 6.4%
* Fasting plasma glucose levels higher than or equal to 6.1 mmol/L but less than 6.9 mmol/L
* Impaired glucose tolerance test (oral glucose challenge)
Screening recommended every 3 years for all patients 40 years of age and older
nonpharmacologinal treatment interventions
Type 1: Always requires insulin therapy
Type 2
* Weight loss
* Improved dietary habits
* Smoking cessation
* Reduced alcohol consumption
* Regular physical exercise
glyemic goal of treatment
- HbA1c of less than 7%
- Fasting blood glucose goal for diabetic patients: 4 to 7 mmol/L
- 2-hour postprandial target of 5 to 10 mmol/L
treatment for diabetes
** Type 1**
Insulin therapy
** Type 2**
Lifestyle changes
Oral drug therapy
Insulin when the above no longer provide glycemic control
types of antidiabetic drugs
- Insulins
- Oral hypoglycemic drugs
- A combination of oral antihypoglycemic and insulin controls glucose levels.
- Some new injectable hypoglycemic drugs may be used in addition to insulin or antidiabetic drugs.
insulins
- Function as a substitute for the endogenous hormone
- Effects are the same as those of normal endogenous insulin
Restores the diabetic patient’s ability to: - Metabolize carbohydrates, fats, and proteins
- Store glucose in the liver
- Convert glycogen to fat stores
human insulin
Human insulin
Derived using recombinant deoxyribonucleic acid (DNA) technologies
Recombinant insulin produced by bacteria and yeast
Goal: tight glucose control
To reduce the incidence of long-term complications
rapid acting treatment for types 1 adn 2 diabetes
Rapid-acting treatment for types 1 and 2 diabetes
* Most rapid onset of action (10 to 15 minutes)
* Peak: 1 to 2 hours
* Duration: 3 to 5 hours
* Patient must eat a meal after injection
* Insulin lispro (Humalog®)
* Action similar to that of endogenous insulin
* Insulin aspart (NovoRapid®)
* Insulin glulisine (Apidra®)
* May be given subcutaneously or via continuous subcutaneous infusion pump (but not intravenously)
short acting insulins
- Regular insulin (Humulin R®, Novolin ge Toronto®)
- Routes of administration: intravenous (IV) bolus, IV infusion, intramuscular, subcutaneous
- Onset (subcutaneous route): 30 minutes
- Peak (subcutaneous route): 2 to 3 hours
- Duration (subcutaneous route): 6.5 hours
intermediate acting insulins
Insulin isophane suspension (also called NPH)
Cloudy appearance
Often combined with regular insulin
Onset: 1 to 3 hours
Peak: 5 to 8 hours
Duration: up to 18 hours